News | April 06, 2026
Samsung Biologics lands first US manufacturing facility with GSK acquisition
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Wholly owned subsidiary KIMS Swastha signs hospital management and sub-lease deal for 210-bed facility, with option to acquire majority stake later
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
The company spotlights micronutrient’s role in immunity, skin and bone health through digital and radio outreach on National Vitamin C Day
Hands-on clinical workshop in Bengaluru brings together neurologists, ENT specialists and physicians
Its a major breakthrough for women’s ovarian cancer care in Europe
The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
Subscribe To Our Newsletter & Stay Updated
